Oxytocin's role in social cognitive changes in ageing
Examining the effects of acute administration of intranasal oxytocin on emotion recognition and related social cognitive functions in healthy ageing
Australian Catholic University
120 participants
Jul 8, 2016
Interventional
Conditions
Summary
The proposed research broadly aims to examine social cognitive changes and neuropeptide mechanisms in healthy older (vs. young) adults. This involves testing the effects of a small dose of acute intranasal OT (relative to placebo) on core social cognitive functions (e.g., emotion recognition, theory of mind), and to test if normal adult ageing is associated with changes in baseline levels of oxytocin and related hormones. We also explore whether individuals' level of functioning influence any of relationships between social cognition and oxytocin.
Eligibility
Inclusion Criteria1
- Participants will be young (18-30 years) and older adults (65-90 years), gender balanced, recruited from the general population. Older adults will also need to pass a well-validated dementia screening assessment involving the Telephone Interview for Cognitive Status .
Exclusion Criteria1
- Since we are interested in examining social cognitive function in the context of normal ageing, we will exclude, for both groups, anyone with neurological/psychiatric illness, substance abuse or dependence, current use of antidepressants or anti-psychotics, history of heart disease, currently smoking, and pregnancy/lactating.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
This study will administer an acute (single) dose of oxytocin (24 IU) nasal spray, once off. Administration of the nasal spray will be guided by the researcher on the day of testing to ensure consistency in the administration of the intervention. Given the study involves a cross-over placebo-controlled design, there will be a washout period of approximately 4 weeks between active (oxytocin) and placebo testing sessions. The 4 weeks allow for the control of menstrual cycle effects in females.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12618001343291